Analytical Data
-
基因名
VEGFA
- Application
-
别名
VEGFA；VEGF；Vascular endothelial growth factor A. long form
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P15692
-
表达区间
27-141aa
-
氨基酸序列
MAPMAEGGGQ NHHEVVKFMD VYQRSYCHPI ETLVDIFQEY PDEIEYIFKP SCVPLMRCGG CCNDEGLECV PTEESNITMQ IMRIKPHQGQ HIGEMSFLQH NKCECRPKKD RARQEKCDKP RR
-
分子量
14 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Recombinant E.coli malE Protein，His
Cat：PA2000-2819
Recombinant Human CCDC67 Protein，His
Cat：PA2000-6513
Protein Description
Vascular endothelial growth factor A (VEGFA) is a crucial protein involved in angiogenesis, the process by which new blood vessels form from pre-existing ones. Its role in promoting endothelial cell proliferation, migration, and survival makes it a key player in various physiological and pathological conditions, including wound healing, tumorigenesis, and cardiovascular diseases. The overexpression of VEGFA is often associated with tumor progression as it stimulates angiogenesis, providing tumors with the necessary nutrients and oxygen for growth. Consequently, understanding VEGFA's mechanisms and interactions has become vital for developing therapeutic strategies against cancer and other diseases characterized by abnormal angiogenesis. Recent advancements in recombinant protein technology have allowed for the production of highly pure and active VEGFA, facilitating in-depth studies of its biological functions and interaction with receptors like VEGFR-1 and VEGFR-2. By utilizing these recombinant proteins, researchers can explore the pathways modulated by VEGFA, assess its potential as a biomarker for disease progression, and evaluate the efficacy of anti-angiogenic therapies. Furthermore, the ability to manipulate VEGFA levels in experimental models provides insights into the molecular mechanisms underlying its diverse roles in health and disease, paving the way for innovative treatment approaches that target VEGFA signaling in various angiogenesis-related conditions.
